Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2011

View Archived Issues

Phase I trial assesses new ruthenium-based anticancer agent NKP-1339 in advanced solid tumors

Phase I data on MLN-4924 in solid tumors suggest antitumor activity

Phase I data on liposomal docetaxel formulation ATI-1123 encourage further clinical study

ALXN-4100TPO counteracts effects of radiation by inducing hematopoietic recovery in vivo

New histamine H3 receptor antagonists presented by Servier

Scientists at Novartis present novel MEK inhibitors

PCI Biotech reports on phase I/II trial of Amphinex/bleomycin combination PC-A11

OCID-2987 is active in models of asthma and COPD

Reduced mGluR5 levels in brain may be biomarker for neurodegeneration in mild cognitive impairment

Almirall and Forest Laboratories report U.S. submission of NDA for aclidinium bromide in COPD

Immune Pharmaceuticals licenses bertilimumab from iCo Therapeutics

Sanofi and Weill Cornell Medical College join to discover new tuberculosis therapies

Basilea Pharmaceutica's BAL-101553 advances to clinic to treat solid tumors

Novartis' phase III GLOW2 trial of NVA-237 in COPD meets primary endpoint

Polyphor claims new beta-hairpin peptidomimetic chemokine CXCR4 receptor antagonists

Roche patents novel monoamine reuptake inhibitors

Novel bile acid GPBA receptor agonists reported by Exelexis

CHMP adopts positive opinion on new Kiovig indication in multifocal motor neuropathy

Zalicus begins phase IIb trial of Synavive in rheumatoid arthritis

Promising preliminary phase IIb data on Anacor's AN-2728 in psoriasis

Vivus seeks approval in U.S. of avanafil for erectile dysfunction

GW Pharmaceuticals starts second phase III Sativex trial

Lux Biosciences to appeal CHMP's negative opinion on Luveniq for noninfectious uveitis

BioLineRx signs license agreement with Yissum Research Development for BL-7040

Alkermes reports promising topline results from phase Ib ALKS-9070 trial in schizophrenia

Viibryd launched in U.S. for treatment of major depressive disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...